NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow grows, but more slowly than its trailing trend

Q2 FY2026 free cash flow of $39.29M (cash outflow) rose 4.1% year over year, behind the +15.6% change in trailing-twelve-month free cash flow. Sequentially, it rose 28.2% from the prior quarter.

Context

  • Free cash flow amounted to 657.8% of revenue in FY2025, up 308.3 pp from a year earlier.
  • Free cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.1% toward the trailing-twelve-month pace of +15.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$39.29M+28.2% QoQ
Last fiscal yearDec 2025
-$148.03M-7.0% YoY
LTMJun 2026
-$143.72M+15.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.1%——
1 year-7.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(148.03M) USD
Year-over-year change
+7.0%

Free Cash Flow vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.6% is the 4th highest of 9, against a peer median of -3.1%.
  • Free cash flow amounts to 2018.3% of revenue for NAMS, versus a peer median of 210.5%.
NAMS Competitors
Free Cash Flow for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNLIDenali Therapeutics Inc.LTM Jun 2026$437.46M USD+18.9%+17.1%12138.1%
VKTXViking Therapeutics, Inc.LTM Jun 2026$418.44M USD+174.3%+79.2%—
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$206.29M USD-33.1%-5.5%16.1%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$143.72M USD+15.6%—2018.3%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$130.02M USD-15.9%-12.2%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$105.55M USD+2.9%+48.5%—
BIOABioAge Labs, Inc.LTM Mar 2026$88.63M USD+64.1%+31.4%859.1%
SEPNSepterna, Inc.LTM Sep 2026$77.59M USD-175.2%—80.6%
ATHEAlterity Therapeutics LimitedFY2025A$11.45M AUD-9.2%-2.7%210.5%
Peer median (excluding NAMS) —-3.1%+17.1%210.5%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Depreciation & Amortization5K9K49K113K220K
Deferred Income Tax00000
Stock-Based Compensation1.24M4.12M24.57M33.62M59.43M
Change in Working Capital4.47M10.37M5.87M(32.67M)(7.94M)
Accounts Receivables0(4.18M)4.03M0(13.28M)
Inventory00000
Accounts Payables6.56M4.81M5.07M(12.95M)4.91M
Other Working Capital(2.09M)9.75M(3.23M)(19.73M)427K
Other Non-Cash Items6.55M18.8M5.23M81.98M4.34M
Operating Cash Flow(29.51M)10.67M(141.22M)(158.56M)(147.78M)
Capital Expenditures(24K)(221K)(24K)(672K)(246K)
Acquisitions (Net)00000
Purchases of Investments000(62.18M)(296.73M)
Sales of Investments0000122.06M
Other Investing Activities00000
Investing Cash Flow(24K)(221K)(24K)(62.85M)(174.92M)
Debt Repayment0747K000
Common Stock Issued84.7M396.95M8.91M645.51M29.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(5.79M)014M0
Financing Cash Flow84.7M391.91M8.91M659.51M29.52M
Effect of Forex Changes(4.68M)5.25M5.05M(6.8M)12.76M
Net Change in Cash50.49M407.6M(127.28M)431.29M(280.42M)
Free Cash Flow(29.54M)10.44M(141.24M)(159.24M)(148.03M)

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.